Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 2627)

RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the "**Company**" or "**Ab&B Bio-Tech**", together with its subsidiary, the "**Group**") pursuant to Rule 13.09(2)(a) and Rule 13.51(4) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated March 31, 2026 in relation to, among others, the suspension of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on Wednesday, April 1, 2026, and the delay in publication of the 2025 Annual Results; and (ii) the announcements of the Company dated April 14 and 24, 2026 in relation to the resignation of auditor and proposed appointment of auditor (collectively, the "**Announcements**").

Unless otherwise stated, capitalized terms used in this announcement shall bear the same meanings as those defined in the Announcements.

RESUMPTION GUIDANCE

On April 24, 2026, the Company received a letter from the Stock Exchange setting out the following guidance for the resumption of trading in the shares of the Company (the "**Resumption Guidance**"):

(i) conduct an appropriate independent forensic investigation into the Fund Investments (including the initial investments and re-investments), the Consultancy Payments, and any other investments or payments of a similar nature or giving rise to similar concerns, assess the impact on the Company's business operations and financial position, announce the findings and take appropriate remedial actions;

(ii) demonstrate that there is no reasonable regulatory concern about the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence;

(iii) engage an independent internal control consultant to conduct an independent internal control review and demonstrate that: (a) the material deficiencies identified in relation to the trading suspension have been rectified and all necessary remedial measures have been implemented; and (b) the internal controls of the Company are adequate and effective to serve their purposes and enable the Company to comply with the Listing Rules in all material aspects, including but not limited to financial reporting, cash management, disclosure and compliance relating to notifiable and connected transactions and disclosure of material information;

(iv) publish all outstanding financial results required under the Listing Rules and address any audit modifications;

(v) demonstrate the Company's compliance with Rule 13.24; and

(vi) inform the market of all material information for the Company's shareholders and investors to appraise the Company's position.

The Company must meet all resumption guidance, remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange's satisfaction before trading in its securities is allowed to resume. The Stock Exchange may modify or supplement the Resumption Guidance if the Company's situation changes.

FURTHER GUIDANCE

Under Rule 6.01A(1), the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period expires on September 30, 2027. If the Company fails to remedy the issues causing its trading suspension, fulfil the Resumption Guidance and fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in its shares by September 30, 2027, the Listing Division will recommend the Listing Committee to proceed with the cancellation of the Company's listing. Under Rules 6.01 and 6.10, the Stock Exchange also has the right to impose a shorter specific remedial period or to cancel the listing of the Company immediately, where appropriate.

Under Rule 3A.19, OCTAL Capital Limited has been appointed as the Company's compliance adviser on August 11, 2025 to provide guidance and advice to the Company as to compliance with the Listing Rules and other applicable laws and regulations upon its listing and up till publication of its financial results for the first full financial year. Given the current circumstances, during the period to which OCTAL Capital Limited is appointed as the Company's compliance adviser (or such replacement under Rule 3A.27), the Company is expected to proactively engage and involve OCTAL Capital Limited throughout the remedial period for the purpose of re-compliance and fulfilment of the Resumption Guidance.

The Company must also comply with the Listing Rules and all applicable laws and regulations in Hong Kong and its place of incorporation before resumption.

The Company must announce the Resumption Guidance and the 18-month period within which it must meet the Resumption Guidance, remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in its shares to avoid delisting as soon as practicable.

While trading is suspended, the Company is also reminded of its obligations under the Listing Rules, including, but not limited to, the following:

(i) keep the duration of any trading suspension to the shortest possible period as required under Rule 6.05;

(ii) comply with its continuing obligations under the Listing Rules at all times, for example, those applying to notifiable and/or connected transactions under Chapters 14 and 14A of the Listing Rules and publication of periodic financial results and reports and, if they are not available, management accounts under Rules 13.46 to 13.49;

(iii) announce inside information required to be disclosed under Part XIVA of the Securities and Futures Ordinance; and

(iv) announce quarterly updates on its developments under Rule 13.24A including, among other relevant matters:

    (a) its business operations;

    (b) its resumption plan with details of actions that it has taken and intends to take to remedy the issues causing its trading suspension, fulfil the Resumption Guidance and fully comply with the Listing Rules and resume trading. The resumption plan should be accompanied with a clear timeframe in respect of each stage of work under the plan with a view that the Resumption Guidance can be fulfilled and trading can resume as soon as practicable and, in any event, before the 18-month period expires;

    (c) the progress of implementing its resumption plan; and

    (d) details of any material change to the resumption plan and, in the case of delay, the reasons and impact of such delay.

The Company must announce its first quarterly update on or before July 1, 2026 and every 3 months from the trading suspension date until resumption or cancellation of listing (whichever is earlier).

CONTINUED SUSPENSION OF TRADING

Trading in the H Shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 and will remain suspended until further notice.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, Chairman of the Board and General Manager

Hong Kong, April 29, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun and Mr. CHEN Chengbei as independent non-executive Directors.